Zacks: Analysts Expect Scpharmaceuticals Inc (SCPH) to Post -$0.53 EPS

Wall Street brokerages expect Scpharmaceuticals Inc (NASDAQ:SCPH) to post earnings of ($0.53) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Scpharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.49). The company is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Scpharmaceuticals will report full year earnings of ($2.12) per share for the current fiscal year, with EPS estimates ranging from ($2.23) to ($2.01). For the next financial year, analysts expect that the business will post earnings of ($2.75) per share, with EPS estimates ranging from ($2.90) to ($2.60). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Scpharmaceuticals.

SCPH has been the topic of a number of research reports. BMO Capital Markets initiated coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set an “outperform” rating and a $24.00 target price on the stock. Leerink Swann initiated coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set an “outperform” rating and a $20.00 target price on the stock. Jefferies Group initiated coverage on shares of Scpharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Scpharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday.

In other news, major shareholder 5Am Partners Iv, Llc acquired 654,762 shares of Scpharmaceuticals stock in a transaction dated Tuesday, November 21st. The shares were bought at an average cost of $14.00 per share, with a total value of $9,166,668.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Several large investors have recently bought and sold shares of the company. Nicholas Investment Partners LP bought a new stake in shares of Scpharmaceuticals in the 4th quarter valued at $1,500,000. AWM Investment Company Inc. bought a new stake in shares of Scpharmaceuticals in the 4th quarter valued at $1,996,000. Monashee Investment Management LLC bought a new stake in shares of Scpharmaceuticals in the 4th quarter valued at $230,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Scpharmaceuticals in the 4th quarter valued at $414,000. 0.07% of the stock is currently owned by institutional investors.

Scpharmaceuticals (NASDAQ:SCPH) traded up $0.32 on Wednesday, reaching $12.46. 12,000 shares of the company’s stock were exchanged, compared to its average volume of 27,751. Scpharmaceuticals has a 52-week low of $11.50 and a 52-week high of $18.17.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/14/zacks-analysts-expect-scpharmaceuticals-inc-scph-to-post-0-53-eps.html.

Scpharmaceuticals Company Profile

scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply